# US Opioid Deaths Drop 38% as Buprenorphine Access Expands, But Fentanyl and New Threats Persist

The opioid epidemic in the United States is showing signs of progress after years of devastation, with overdose deaths dropping nearly 38% from 109,703 in October 2023 to 68,408 in October 2025, according to provisional data from the U.S. Centers for Disease Control and Prevention cited by the American Medical Association. Despite this decline, the crisis remains deadly and evolving, fueled primarily by illicitly manufactured fentanyl, which drove most of the roughly 75,000 opioid-related deaths in 2025, as detailed in a recent AMA report. Nearly 60% of these fatalities now involve polysubstance use, making the illegal drug supply more toxic and unpredictable than ever, warns AMA CEO John Whyte.

Listeners, the good news stems from expanded access to life-saving treatments like buprenorphine, with prescriptions surging from 1.4 million in 2012 to 15.4 million in 2024, per the AMA. Groups like the AMA, American Society of Addiction Medicine, and American Pharmacists Association emphasize that affordable, evidence-based care must lead the charge, as highlighted at the 15th Annual Rx and Illicit Drug Summit in Nashville. Yet challenges persist: in Hennepin County, Minnesota, fentanyl was linked to 86% of opioid deaths from January to June 2025, according to a county opioid response update, even as overall trends dipped before rising mid-year.

A new threat has emerged with medetomidine, a veterinary sedative not approved for humans, increasingly contaminating the illicit supply. The CDC's April 2 Health Alert Network advisory warns it causes profound sedation, slow heart rate, low blood pressure, and severe withdrawal symptoms like hypertension and anxiety that may require intensive care. Since fentanyl often mixes with it, naloxone remains essential for reversing overdoses by restoring breathing, the CDC advises. Meanwhile, a fresh study reveals naloxone's limitations against super-potent synthetics like fentanyl and sufentanil, with current doses sometimes failing to fully reverse overdoses, as reported in the UCAC Weekly Newsletter.

Federal and state responses are ramping up. The Congressional Budget Office outlines strategies including disrupting illicit supply chains, boosting Medicaid coverage for treatment, expanding telehealth, aiding those in the criminal justice system, and increasing naloxone access, which have proven to cut use and overdoses. The AMA urges eliminating prior authorizations for medications like buprenorphine an

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI

This episode includes AI-generated content.